Drug Trial Radar · NCT04774406
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Last checked: Nov 19, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,336
Actual
Start
Feb 24, 2021
Primary completion
May 9, 2021
Study completion Sep 1, 2022
Sponsor
- Lead sponsor
- University Hospital, CaenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Conditions
- Cancer
Interventions
olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparibDrug
All patients treated at least with 1 PARPi (alone or in combination)
Primary outcomes
What the sponsor says the trial is designed to measure.
- hypertension reports related to PARPi.Time frame: From inception to 16 Feb, 2023
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexandre Joachim
Caen, Basse Normandie, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.